MedTrace Logo

TACE as an Adjuvant Therapy After Hepatectomy for HCC

NCT01966133 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2017-01-09

No results posted yet for this study

Summary

Investigators hypothesise that the use of transarterial chemoembolisation (TACE) after liver resection in patients with hepatocellular carcinoma can eradicate residual cancer cells in the liver and thus improve survival of patients with high risk factors for residual tumor. The aim of this study is to compare the survival of patients with high risk factors for residual tumor undergoing liver resection plus post-operative TACE versus liver resection alone.

Conditions

Interventions

DRUG

Ethiodized Oil + Doxorubicin

TACE using doxorubicin-lipiodol mixture

Sponsors & Collaborators

  • Jia Fan

    lead OTHER

Principal Investigators

  • Jia Fan, MD · Liver cancer institute, Fudan university

  • Jian Zhou, MD · Liver Cancer Institute, Zhong Shan Hospital, Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2016-08-31
Completion
2017-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01966133 on ClinicalTrials.gov